After Zogenix announced that the FDA has extended the PDUFA date for Fintepla by three months to allow more time to review additional data submitted by the company, Mizuho analyst Difei Yang noted that management told her that the additional data were related to efficacy only, not safety, and required no additional clinical trials. She identified a number of precedent cases of PDUFA date extensions where the drugs ultimately gained approval and sees the pullback in Zogenix shares as an attractive buying opportunity, added Yang, who keeps a Buy rating on the stock.